Nanomedicine: developing smarter therapeutic and diagnostic modalities.

By O. Farokhzad, Robert Langer. Advanced Drug Delivery Reviews, 2006

772 citations recorded by the source corpus.

Subfields: Biomaterials, Materials Chemistry, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/f1456f10c22817477beabaad2d3b3a3fd93f6618

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. J. Hanes
2. N. Bertrand
3. N. Kamaly
4. O. Farokhzad
5. Xiaoyang Xu
6. Liangfang Zhang
7. Jun Wu
8. Omid Veiseh

In Materials Chemistry

1. Arturo Keller
2. Anastasiya Lazareva
3. Paul C. Wang
4. O. Farokhzad
5. R. Sridhar
6. Stephen Lin
7. Jun Wu
8. Sangwon Suh

In Molecular Biology

1. J. Hanes
2. O. Farokhzad
3. N. Bertrand
4. N. Kamaly
5. Xiaoyang Xu
6. Jun Wu
7. Liangfang Zhang
8. Paul C. Wang

Citations in the corpus

• Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues (2008, background): “Nanoparticle systems can be engineered to possess a number of desirable features for therapy, including: (i) sustained and controlled release of drugs locally [5,6], (ii) deep tissue penetration due to the nano-metric size [7–9], (iii) cellular uptake and sub-cellular trafficking [10,11], and (iv) p”
• Global life cycle releases of engineered nanomaterials (2013, background): “2006; Blasco and Picó 2011); medical (Farokhzad and Langer 2006; Boisseau and Loubaton 2011); packaging (Silvestre et al.”
• Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, background): “Since then, the proof of concept was achieved in vivo for NPs incorporating multiple types of drug [160, 161, 241, 287, 288].”
• Organ-on-a-Chip Platforms for Studying Drug Delivery Systems (2014, neutral): “The rapidly developing field of nanomedicine can significantly impact human disease therapy [1,2].”
• Development of nanoparticles for antimicrobial drug delivery. (2010, background): “In 1995, Doxil (doxorubicin liposomes) became the first liposomal delivery system approved by the Food and Drug Administration (FDA) to treat AIDS associated Kaposi ’s sarcoma [11, 12].”
• Techniques for physicochemical characterization of nanomaterials (2013, background): “These physiological interactions may provide benefits in medical applications, including improvements in efficacy, reduction of side effects, prevention and treatment (Farokhzad and Langer, 2006; Hall et al., 2007).”
• Endocytosis of Nanomedicines (2010, background): “The concept of active targeting of nanomaterials using antibodies, polypeptides, aptamers and other targeting groups, has generated tremendous interest and on a surface appears to be simple [3,84].”
• Nanotechnological applications in medicine. (2007, background): “Owing in part to the national nanotechnology initiatives, there has been much activity in applying nanotechnology to therapeutics [38–41,42 ].”